XTL Biopharmaceuticals Ltd. Stock TEL AVIV STOCK EXCHANGE
Equities
XTLB
IL0010854979
Biotechnology & Medical Research
Sales 2021 | - | Sales 2022 | - | Capitalization | 6.36M 24.09M |
---|---|---|---|---|---|
Net income 2021 | - 0 | Net income 2022 | -1M -3.79M | EV / Sales 2021 | - |
Net cash position 2021 | 6.13M 23.2M | Net cash position 2022 | 3.72M 14.09M | EV / Sales 2022 | - |
P/E ratio 2021 |
39.2
x | P/E ratio 2022 |
-4.72
x | Employees | - |
Yield 2021 * |
-
| Yield 2022 |
-
| Free-Float | 93.3% |
Managers | Title | Age | Since |
---|---|---|---|
Shlomo Shalev
CEO | Chief Executive Officer | 62 | 14-12-29 |
Itay Weinstein
DFI | Director of Finance/CFO | 52 | 98-12-31 |
Doron Turgeman
CHM | Chairman | 56 | 14-12-29 |
Members of the board | Title | Age | Since |
---|---|---|---|
Shlomo Shalev
CEO | Chief Executive Officer | 62 | 14-12-29 |
Director/Board Member | 56 | 20-01-28 | |
Director/Board Member | 53 | 17-03-31 |
1st Jan change | Capi. | |
---|---|---|
+3.90% | 43.43B | |
+47.81% | 41.69B | |
+9.16% | 41.31B | |
-10.92% | 27.14B | |
+8.56% | 25.28B | |
-24.58% | 18.47B | |
+29.06% | 12.59B | |
+0.80% | 12.33B | |
+9.53% | 11.03B |